drugset / Trial / NCT00241176
Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if Abilify will reduce tics (repetitive, uncontrollable movements or vocalizations) in children and adolescents ages 7-18 with Tourette's Disorder (TD) or a chronic motor tic disorder (either repetitive, uncontrollable movements or vocalizations).
Timeline
- Start
- 2005-09
- Primary completion
- 2008-08
- Completion
- 2010-02
Outcome
Met primary endpoint
registry analysis (superiority or other test); Group 1 - Baseline vs Group 1 - Endpoint; p <.05; Mean Difference (Final Values) .003; Wilcoxon (Mann-Whitney) NCT00241176 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aripiprazole | Other / unclassified | 1.25 mg | — |
| Subject | Aripiprazole | Other / unclassified | 2.5 mg | — |
| Subject | Aripiprazole | Other / unclassified | 3.75 mg | — |
| Subject | Aripiprazole | Other / unclassified | 5 mg | — |
| Subject | Aripiprazole | Other / unclassified | 7.5 mg | — |
| Subject | Aripiprazole | Other / unclassified | 10 mg | — |
| Subject | Aripiprazole | Other / unclassified | 12.5 mg | — |
| Subject | Aripiprazole | Other / unclassified | 15 mg | — |